Published in Oncol Rep on August 07, 2012
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol (2015) 1.04
α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer (2012) 0.91
MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines (2014) 0.91
Antigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model. Radiology (2014) 0.89
Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer (2014) 0.88
Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation. Mol Clin Oncol (2013) 0.80
Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol (2016) 0.80
Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res (2014) 0.80
Inactivation of DNA-dependent protein kinase promotes heat-induced apoptosis independently of heat-shock protein induction in human cancer cell lines. PLoS One (2013) 0.79
Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients. Oncoimmunology (2013) 0.79
A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes. PLoS One (2015) 0.78
Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Gene Ther (2015) 0.77
Insights into dendritic cell function using advanced imaging modalities. Virulence (2012) 0.77
Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines (Basel) (2016) 0.77
Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene. J Cancer Res Clin Oncol (2013) 0.76
New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med (2015) 0.76
Tumor Vaccines for Malignant Gliomas. Neurotherapeutics (2017) 0.75
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight (2017) 0.75
Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther (2013) 0.75
Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines. Oncol Rep (2016) 0.75
CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors. J Immunol Res (2014) 0.75
Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma. Oncotarget (2016) 0.75
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology (2016) 0.75
Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies. Bioimpacts (2015) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 4.20
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 3.67
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res (2001) 3.01
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 2.45
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res (2011) 2.10
Serum autoantibodies as biomarkers for early cancer detection. FEBS J (2009) 1.94
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine (2007) 1.58
A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res (2002) 1.56
MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer (2009) 1.53
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer (2001) 1.52
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate (2004) 1.50
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother (2000) 1.24
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother (2003) 1.21
Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother (2001) 1.09
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest (2000) 1.02
Humoral response to cancer as a tool for biomarker discovery. J Proteomics (2009) 0.99
Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res (2010) 0.97
Identifying autoantibody signatures in cancer: a promising challenge. Expert Rev Proteomics (2009) 0.95
Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother (2002) 0.91
Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med (2005) 0.89
Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev Anticancer Ther (2011) 0.88
Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother (1998) 0.84
Identification of cytomegalovirus (CMV)pp65 antigen-specific human monoclonal antibodies using single B cell-based antibody gene cloning from melanoma patients. Immunol Lett (2010) 0.79
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
The outcome and repair integrity of completely arthroscopically repaired large and massive rotator cuff tears. J Bone Joint Surg Am (2004) 5.62
Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One (2010) 3.23
Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan. Arch Dermatol (2004) 2.62
Detection and quantification of rotator cuff tears. Comparison of ultrasonographic, magnetic resonance imaging, and arthroscopic findings in seventy-one consecutive cases. J Bone Joint Surg Am (2004) 2.44
American Academy of Orthopaedic Surgeons Clinical Practice Guideline on: optimizing the management of rotator cuff problems. J Bone Joint Surg Am (2012) 2.20
Symptomatic progression of asymptomatic rotator cuff tears: a prospective study of clinical and sonographic variables. J Bone Joint Surg Am (2010) 2.13
Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol (2008) 1.63
Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood (2010) 1.42
Factors affecting healing rates after arthroscopic double-row rotator cuff repair. Am J Sports Med (2010) 1.39
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother (2008) 1.38
Self-involution of giant keratoacanthoma on the tip of the nose. Plast Reconstr Surg (2003) 1.37
Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol (2009) 1.34
Sonography of the rotator cuff: analysis of interobserver variability. AJR Am J Roentgenol (2004) 1.29
Shoulder strength in asymptomatic individuals with intact compared with torn rotator cuffs. J Bone Joint Surg Am (2009) 1.28
Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol (2011) 1.26
Metastatic angiosarcoma of the lung: spectrum of CT findings. AJR Am J Roentgenol (2003) 1.26
Accuracy of ultrasound imaging of the rotator cuff in shoulders that are painful postoperatively. J Bone Joint Surg Am (2003) 1.26
Tendon integrity and functional outcome after arthroscopic repair of high-grade partial-thickness supraspinatus tears. J Bone Joint Surg Am (2009) 1.25
Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer (2007) 1.21
PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res (2013) 1.17
Location and initiation of degenerative rotator cuff tears: an analysis of three hundred and sixty shoulders. J Bone Joint Surg Am (2010) 1.17
The efficacy of ultrasound in the diagnosis of long head of the biceps tendon pathology. J Shoulder Elbow Surg (2006) 1.16
Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2008) 1.15
Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation (2007) 1.15
Sonography and MRI of the shoulder: comparison of patient satisfaction. AJR Am J Roentgenol (2004) 1.15
Insertional anatomy of the triceps brachii tendon. J Shoulder Elbow Surg (2010) 1.13
Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res (2004) 1.12
Proximal humeral migration in shoulders with symptomatic and asymptomatic rotator cuff tears. J Bone Joint Surg Am (2009) 1.11
Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood (2005) 1.09
The posterior branch of the axillary nerve: an anatomic study. J Bone Joint Surg Am (2003) 1.07
Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS One (2013) 1.06
Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant (2008) 1.06
Optimizing the management of rotator cuff problems. J Am Acad Orthop Surg (2011) 1.06
Cigarette smoking increases the risk for rotator cuff tears. Clin Orthop Relat Res (2009) 1.06
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer (2011) 1.05
Pectoralis major transfer for anterior-superior subluxation in massive rotator cuff insufficiency. J Shoulder Elbow Surg (2003) 1.04
Asymptomatic rotator cuff tears: patient demographics and baseline shoulder function. J Shoulder Elbow Surg (2010) 1.04
Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development. Int J Oncol (2010) 1.01
Nonoperative treatment for osteochondritis dissecans of the capitellum. Am J Sports Med (2008) 1.01
Detection and measurement of rotator cuff tears with sonography: analysis of diagnostic errors. AJR Am J Roentgenol (2005) 1.00
Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood (2012) 1.00
Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med (2004) 1.00
Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep (2008) 1.00
Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics (2010) 0.99
Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials. J Immunother (2005) 0.99
Diagnostic performance and reliability of ultrasonography for fatty degeneration of the rotator cuff muscles. J Bone Joint Surg Am (2012) 0.99
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol (2012) 0.99
Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol (2003) 0.99
Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood (2006) 0.98
Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res (2002) 0.98
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood (2009) 0.98
[A case of transient left ventricular ballooning ("Takotsubo"-shaped cardiomyopathy) developed during plasmapheresis for treatment of myasthenic crisis]. Rinsho Shinkeigaku (2004) 0.98
Changes in the expression of CD106, osteogenic genes, and transcription factors involved in the osteogenic differentiation of human bone marrow mesenchymal stem cells. J Bone Miner Metab (2008) 0.97
Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett (2011) 0.97
A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation (2005) 0.96
Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation (2002) 0.96
Relationship of radiographic acromial characteristics and rotator cuff disease: a prospective investigation of clinical, radiographic, and sonographic findings. J Shoulder Elbow Surg (2012) 0.96
Revision arthroscopic rotator cuff repair: repair integrity and clinical outcome. J Bone Joint Surg Am (2010) 0.96
Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence. Med Oncol (2011) 0.95
Arthroscopic treatment of post-traumatic elbow contracture. J Shoulder Elbow Surg (2002) 0.95
Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant (2005) 0.94
Quantitative metabolome profiling of Illicium anisatum by capillary electrophoresis time-of-flight mass spectrometry. Biomed Res (2010) 0.94
MRI findings of mediastinal neurogenic tumors. AJR Am J Roentgenol (2011) 0.94
Clinical and radiographic outcomes of failed repairs of large or massive rotator cuff tears: minimum ten-year follow-up. J Bone Joint Surg Am (2013) 0.94
Efficacy of taxane regimens in patients with metastatic angiosarcoma. Eur J Dermatol (2011) 0.94
Relation of the radial nerve to the anterior capsule of the elbow: anatomy with correlation to arthroscopy. Arthroscopy (2012) 0.93
Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant (2007) 0.93
Large-cell neuroendocrine carcinoma of the skin, with lymphoid stroma. Am J Dermatopathol (2007) 0.93
Identification of a novel protein isoform derived from cancer-related splicing variants using combined analysis of transcriptome and proteome. Proteomics (2011) 0.93
Relationship of tear size and location to fatty degeneration of the rotator cuff. J Bone Joint Surg Am (2010) 0.93
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci (2010) 0.93
Imaging algorithms for evaluating suspected rotator cuff disease: Society of Radiologists in Ultrasound consensus conference statement. Radiology (2013) 0.93
Applicability of radiocolloids, blue dyes and fluorescent indocyanine green to sentinel node biopsy in melanoma. J Dermatol (2011) 0.92
Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res (2003) 0.92
High transgene expression by lentiviral vectors causes maldevelopment of Purkinje cells in vivo. Cerebellum (2010) 0.91
Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker. Proteomics Clin Appl (2008) 0.91
α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer (2012) 0.91
Axillary giant lipoma: a report of two cases and published work review. J Dermatol (2014) 0.91
Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer (2005) 0.91
Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog (2013) 0.91
Mutant PKCγ in spinocerebellar ataxia type 14 disrupts synapse elimination and long-term depression in Purkinje cells in vivo. J Neurosci (2011) 0.91